Recently, gene expression profiling and additional immunohistochemical studies have suggested that TOX might represent a potential marker for the histological diagnosis of CTCL, being aberrantly expressed in CD4 neoplastic T cells in MF and Sezary syndrome [27]. Here, CD4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.